The market for antibiotics is expected to grow at a CAGR of around 4.6% from 2020 to 2027 and expected to reach the market value of around US$ 57.1 Bn by 2027.
Antibiotics are medicines that help in fighting against bacterial infection in humans as well as animals. They basically kill the bacteria or prevent them from growing and multiplying in the host. Additionally, the antibiotics can be taken in different ways that include orally, topically, or intravenously according to the requirement of the person or the intensity of the infection.
The development of advanced products by the major manufacturers along with the increasing infectious diseases burden is driving the market growth.
The increasing prevalence of infectious diseases such as lower respiratory infections, malaria, pneumonia, and tuberculosis are supporting the demand in the global market. The growing number of collaborations for the development of antibiotics among the major players is additionally bolstering the market value. The government and non-government bodies are increasing their investment budget in R&D initiatives and to boost the development of novel antibiotics and supportive regulatory policies due to increasing disease burden is further bolstering the market growth. Furthermore, the discovery of advanced prospect molecules, as well as the introduction of novel combination therapies to treat antibiotic-resistant microbial infections, is likely to create potential opportunities over the forecast period.
On the other side, high R&D cost and development of resistance against antibiotics are the factors likely to limit the growth to an extent during the estimated period.
Global Antibiotics Market Revenue (US$ Mn)
Broad-spectrum Antibiotic is the leading segment in the global antibiotics market
On the basis of spectrum, the broad-spectrum antibiotic is the leading segment in the global antibiotics market. These are active against a wider number of bacterial types and, thus have a demand for the treatment of a variety of infectious diseases. These are mostly used when the bacterial infection is suspected but the group of bacteria is unknown or in the case when infection with multiple groups of bacteria is suspected. The ability to treat a wider range of bacterial infections is primarily bolstering the segmental market value.
Asia Pacific dominated the Antibiotics Market with major revenue share in the year 2019
In 2019, Asia Pacific dominated the global market with maximum revenue share, and the region is also estimated to maintain its dominance over the forecast period from 2020 to 2027. The excessive consumption of antibiotics, increasing prevalence of infectious diseases, presence of generic players, unregulated sales, and rapidly developing economies of the region are supporting the regional market growth. The major developing economies of the region including China and India are the major revenue contributors. Additionally, the region is also projected to exhibit the fastest growth over the forecast period. Moreover; the Asia Pacific is followed by North America in the antibiotics market. The increasing burden of infectious resistant diseases is contributing to the regional market growth.
According to the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health & Human Services, around 2.8 million antibiotic-resistant infections occur each year in the U.S. and result in more than 35,000 deaths. The US is working to reduce the number of infections and deaths caused by antibiotic-resistant germs.
Key Players Profiled
The players profiled in the report include Abbott Laboratories, Allergan plc, Basilea Pharmaceutica Ltd., Bayer Healthcare AG, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Inc., Melinta Therapeutics, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, and Tetraphase Pharmaceuticals.
Market By Product Type
Other Product Types
Market By Drug Origin
Market By Spectrum
Market By Route of Administration
Market By Distribution Channel
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
The market for antibiotics is expected to reach a market value of around US$ 57.1 Bn by 2027.
The antibiotics market is expected to grow at a CAGR of around 4.6% from 2020 to 2027.
Broad-spectrum antibiotic is the leading segment by spectrum in the antibiotics market
The development of advanced products by the major manufacturers, increasing prevalence of infectious diseases, growing number of collaborations for the development of antibiotics, government and non-government bodies are increasing their investment budget in R&D initiatives and to boost the development of novel antibiotics are some of the factors driving the market growth.
Abbott Laboratories, Allergan plc, Basilea Pharmaceutica Ltd., Bayer Healthcare AG, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Inc., Melinta Therapeutics, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, and Tetraphase Pharmaceuticals are the prominent players in the market.
Asia Pacific held the highest market share in the antibiotics market
Asia Pacific is expected to be the fastest growing market over the forecast period